|
|
Post by suebeeee1 on Oct 31, 2015 15:21:10 GMT -5
I know you meant mnkd management can effectively do nothing regarding Afrezza sales. Move, set up lines. sell buildings. Mannkind got Technosphere in June of 2014 as well. Mannkind has been working also on technosphere applications. And Patents. Afrezza patents, technospere insulin. Now comes the ramp up. This insulin, technosphere insulin is one fine medication. Technosphere, the platform, pharma's eyeballs have to be popping out. Eye on the ball. I watched an interview with Al Mann. "He said, when the science showed him technosphere, he knew. " My words, he must be some kind of super seer.
Technosphere is IT. All Mann knew it when he saw the science. I, a freaking liberal arts major, knew the science was simple, elegant and mind blowing incredible. But so did you and a few hundred thousands of others!. That is why we all hang out here singing its praises. While Afrezza is a great product and game changer, think about all the meds needing to have super fast results. They will ALL be delivered by Technosphere within a few years. Again, it is just a matter of time. |
|
|
|
Post by peppy on Oct 31, 2015 16:27:45 GMT -5
And the patents.
Have you seen the patents?
I do not think the market capitalization is valuating the patents.
(If I understood exactly what I am looing at when Lakers (and all) post the patents under the resources board, I would organize them in a thread and count.)
|
|
|
|
Post by backwash on Oct 31, 2015 16:31:35 GMT -5
backwash - Re: "...I do have enough experience to know investing in proven leadership is a key component to a successful long term outcome with any type of investment.". Are you frustrated at MNKD management, or at yourself for not identifying what you believe are management 'flaws' prior to investing?
If I lose it’s my fault. Whether its Buffet or Icahn, the first thing a prudent investor looks at is management. Every sensible investor does…..if the big boys don’t like the leadership in a company they change it. Look at VRX which just got hammered by the shorts, the first thing people talk about on the street…..does the CEO have the skill set to stop the bleeding and regain support of the investment community. Go Pro is another company whose management is currently under the microscope for not delivering. Take Bill Gross at PIMCO-some people thought he lost the touch….the list goes on and on.
My question is fair (not FUD) and still remains unanswered. Do the current CEO and CFO have what it takes to maximize the value of MNKD’s assets? The only way to answer that question is to cite an example-I can’t find anything anywhere that answers that question one way or another.
While I do not wish anyone ill regarding any aspect of their life, including their investments, my main concern is protecting my assets, and part of that is asking simple questions. This board seems like a good lot with members knowledgeable about the company-that’s why I chimed in.
Buy and hold is my preference, I’ve had some of the oil service companies for over thirty years. Many of you know, that sector is like biotech – volatile. The ones I own have proven management that know what to do when oil prices collapse-as they do.
Good luck
|
|
|
|
Post by peppy on Oct 31, 2015 16:39:29 GMT -5
backwash - Re: "...I do have enough experience to know investing in proven leadership is a key component to a successful long term outcome with any type of investment.". Are you frustrated at MNKD management, or at yourself for not identifying what you believe are management 'flaws' prior to investing? If I lose it’s my fault. Whether its Buffet or Icahn, the first thing a prudent investor looks at is management. Every sensible investor does…..if the big boys don’t like the leadership in a company they change it. Look at VRX which just got hammered by the shorts, the first thing people talk about on the street…..does the CEO have the skill set to stop the bleeding and regain support of the investment community. Go Pro is another company whose management is currently under the microscope for not delivering. Take Bill Gross at PIMCO-some people thought he lost the touch….the list goes on and on. My question is fair (not FUD) and still remains unanswered. Do the current CEO and CFO have what it takes to maximize the value of MNKD’s assets? The only way to answer that question is to cite an example-I can’t find anything anywhere that answers that question one way or another. While I do not wish anyone ill regarding any aspect of their life, including their investments, my main concern is protecting my assets, and part of that is asking simple questions. This board seems like a good lot with members knowledgeable about the company-that’s why I chimed in. Buy and hold is my preference, I’ve had some of the oil service companies for over thirty years. Many of you know, that sector is like biotech – volatile. The ones I own have proven management that know what to do when oil prices collapse-as they do. Good luck yep screencast.com/t/cr8dKnfigJ0I ADDED: which is a perfect case in point in this regard. OPEC had pumped USA oil for decades. After the great recession of 2009, fracking in the USA picked pick, as world demand went down, ***Point so, the Saudi's lowered the price of oil, fracking almost bust now, which their debt burden. Point, mankind shorting attempt to make the business fail. I see a business strategy resemblance.
|
|
|
|
Post by EveningOfTheDay on Oct 31, 2015 17:04:12 GMT -5
If I lose it’s my fault. Whether its Buffet or Icahn... ... The ones I own have proven management that know what to do when oil prices collapse-as they do. You should rest assured that this is the same team of people that, against pretty significant odds, have managed to bring to market an absolutely revolutionary drug. If that does not deserve a vote of confidence, I do not know what it does. |
|
|
|
Post by backwash on Nov 1, 2015 9:03:40 GMT -5
The comment earlier...You should rest assured that this is the same team of people that, against pretty significant odds, have managed to bring to market an absolutely revolutionary drug. If that does not deserve a vote of confidence, I do not know what it does.
You are spot on. Current management deserves thumbs up for getting approvals. Pre-clinical through phase 1, 2 & 3 is an arduous task. Now investors want to be rewarded for years of funding the process-that’s how it works. Right or wrong-when a company goes to the street for capitalization ( private to public entity) the investment community judges that company every quarter, every day, actually every minute of the trading day –these are the capital markets.
MNKD management is well-paid by their investors and their investors want results (I’m guessing not everyone here has the benefit of just forgetting about their investments and gifting it to their kids or alma mater and hope it all works out) .
Investors can go long, go short, buy calls or puts and everything in between. Right now the bet is against management. The share price has flopped and by many standards so has the roll out of their product with SNY (no fud just facts). Bottom line….since approval- current management has given all the ammo the shorts need to continue on…….cannot argue with the tape/meaning the share price.
I like to buy when nobody else does. I am comfortable with my entry points and again own the leaps. Again/I believe in the product and the technosphere platform and I like the benefits of their billion dollar loss carryover for tax purposes-should they get that far. If Al Mann were 20 years younger, I might be more inclined to put this on cruise control-as he has gutted these things out before.
When I started investing we put Proctor & Gamble, J&J, Chevron and Unocal, Security Pacific Bank shares under our mattress, collected the dividends and watched the corn grow. Times have changed, globalization and currency fluctuations play a big part with earnings AND Wall Street has less patience. It used to be you were not entitled to wealth until you were a gray hair or a Rockefeller. The Facebook’s, Ubers, Twtr changed all that – these are exciting times – pick the right leadership, along with a little luck and watch your money grow/faster than ever. That’s why we are here-and this is what we expect from MNKD mgmt... part of the process is ongoing evaluation.
A famous fund manager made a comment something along these lines last week. Reporter asked him if he was scared of this mkt/his reply. I am always scared, if your not, you should not get involved.
|
|
|
|
Post by mssciguy on Nov 1, 2015 9:21:32 GMT -5
backwash Not sure what you are getting at, many good points, but it's Sanofi that's bringing the drug to market-- all praise or blame currently rests with Sanofi. MNKD got the drug approved despite attacks by Shrekeli (who, meanwhile, profited as a short, borderline criminal) and despite the fact that three big pharmas spent billions on their inhaled insulins but failed. Does MNKD mgmt interact with Sanofi regarding Afrezza marketing? Apparently since we've heard that things will turn around at a future date several times... it IS frustrating to have vague guidance or none at all, and this is the company Wall Street loves to hate. In hindsight, would I have put this much of my money here, no, but I wouldn't have put it anywhere else except for daytrading ETFs which was working wonderfully for a while. Your reservations are well taken. I watch Indeed for "particle inhalation scientist" among other positions as well as some other areas from time to time and for sure, competition is brewing for what once seemed a monopoly by MNKD. If we don't see something tangible soon, mgmt will only have itself to blame and will be forced to pursue other options. There is a legal obligation to shareholders, and mgmt holds plenty of shares itself. Not sure if this helps... welcome to the world of microcap growth stocks.
|
|
|
|
Post by backwash on Nov 1, 2015 11:08:25 GMT -5
backwash Not sure what you are getting at, many good points, but it's Sanofi that's bringing the drug to market-- all praise or blame currently rests with Sanofi. MNKD got the drug approved despite attacks by Shrekeli (who, meanwhile, profited as a short, borderline criminal) and despite the fact that three big pharmas spent billions on their inhaled insulins but failed. Does MNKD mgmt interact with Sanofi regarding Afrezza marketing? Apparently since we've heard that things will turn around at a future date several times... it IS frustrating to have vague guidance or none at all, and this is the company Wall Street loves to hate. In hindsight, would I have put this much of my money here, no, but I wouldn't have put it anywhere else except for daytrading ETFs which was working wonderfully for a while. Your reservations are well taken. I watch Indeed for "particle inhalation scientist" among other positions as well as some other areas from time to time and for sure, competition is brewing for what once seemed a monopoly by MNKD. If we don't see something tangible soon, mgmt will only have itself to blame and will be forced to pursue other options. There is a legal obligation to shareholders, and mgmt holds plenty of shares itself. Not sure if this helps... welcome to the world of microcap growth stocks. Some people that are just evil.....Shrekeli is one. On a positive note, I saw something VERY encouraging last week. When SNY lowered guidance, they took MNKD to low three’s. I thought we were going to 2’s then the buyers came in. Recent action in the stock leads me to believe (just a hunch) something really good is about to happen. My position with MNKD or with any other investment……. Tell me the good, bad or ugly and I will decide. Leaving people in the dark is wrong. That guy is a punk. |
|
|
|
Post by EveningOfTheDay on Nov 1, 2015 15:23:37 GMT -5
MNKD management is well-paid by their investors and their investors want results (I’m guessing not everyone here has the benefit of just forgetting about their investments and gifting it to their kids or alma mater and hope it all works out) . Investors can go long, go short, buy calls or puts and everything in between. Right now the bet is against management. The share price has flopped and by many standards so has the roll out of their product with SNY (no fud just facts). Bottom line….since approval- current management has given all the ammo the shorts need to continue on…….cannot argue with the tape/meaning the share price. You are right, at this moment the bet is against management, the latest issue shorts have decided would give them an edge, but up until recently the bet was against partnership, approval, etc, etc, etc. Alfred Mann might be a mighty man, but the interests that would like to see this fail are also mighty and, apparently, will stop at nothing. Those interest include a short position that, in my humble opinion, have, by betting on the non-viability of Afrezza, set themselves in an extremely delicate spot. I personally remain unsure of whether is mathematically possible for them to attempt to cover without creating a very steep rise in the share price. The only way they can do this, in my opinion is to continuously discourage outstanding and possible investors to the point that everybody is waiting to see what will happen before buying in, while exploiting every piece of news as a negative, creating a level of uncertainty that allows for a high degree of share price manipulation. Lo and behold, that is exactly what we are seeing day in and day out. In addition, I find fairly possible, even though I have been told before that was just my paranoia acting up, that some of this short positions are backed by interest other than purely financial. Interests that might not want to see Afrezza or Technosphere succeed in any capacity, or at least delay that success for as long as it is possible because it presents a direct threat to their bread and butter, or if you prefer their livelihood. Given all this, it is not surprising at all that the bet, as you call it, is now against management and, by extension, against Sanofi's interest to market, since only few would question their ability. Again, this is not a surprise, since it has become pretty obvious that Afrezza is not only a great drug with great potential, but also that it could open the door to Technosphere in a huge way. Those facts are, for most objective observers, almost undebatable, given the increasing number of reports that users have slowly been leaking over the last few months. So my questions remains, why would you, if you have no faith on management, and given that your own investment strategy absolutely requires a management that offers you a certain level of confidence, want to stay invested into MNKD. My guess is that you too see what is happening and hope that eventually things will be put where they truly belong. Management has a plan to execute and they do need time for it. It might require fine tuning, but given the pressure they are being submitted to without breaking, and the obstacles they have overcome in the past, my personal assessment is that they do deserve that time. |
|
|
|
Post by backwash on Nov 2, 2015 7:24:27 GMT -5
So my questions remains, why would you, if you have no faith on management, and given that your own investment strategy absolutely requires a management that offers you a certain level of confidence, want to stay invested into MNKD
That’s actually a very good question-I like it!
Here is my best reply. I am long Afrezza, and the prospects of Technosphere.
I am short (that’s an awful term here but for this explanation I will use it) managements execution post Afrezza`s approval. Should Afrezza flop big time, the Technosphere platform will not be worth as much as it is today, and MNKD does not have the money to fund another pipeline? Securing funding from the capital mkts for another technosphere application in absence of an outright Afrezza success would be difficult and further dilution massive.
My Solution: Hedge the long position.
Time to realization: 2-3 weeks. Meaning I think investors will learn what they need to know in the next 14-21 days ….from today. Between the required disclosures and SNY game plan we should be better informed very soon.
|
|
|
|
Post by mbseeking on Nov 2, 2015 8:32:06 GMT -5
We need tangible acts from SNY. Clinical trials with Afrezza the focus not in a supporting role, would be a start and probably the only solution required.. From what I can tell they have done close to zero so far , expecting Afrezza to sell itself. I'm still of the opinion if they address insurance it will indeed sell itself.
The jury is still out on SNY.. but after last week I believe evidence is mounting that they will not do what needs to be done.
|
|
|
|
Post by peppy on Nov 2, 2015 8:46:36 GMT -5
|
|
|
|
Post by peppy on Nov 2, 2015 9:14:17 GMT -5
help me out here, so many of you have sat in board rooms.
Possible scenario:
Sanofi diabetes unit: "we have lost patent on Lantus have introduced toujeo, have lost some revenue there. No big change in revenue expected in the insulin analogue market.
We do however have afrezza, which could revolutionize diabetes treatment and we are the only ones that have it.
Once included in the standards of care, we are set, as the diabetes market type 1 and 2 are huge."
Scenario 2: Afrezza didn't sell it's self yet. we could pull the plug now. Physician feed back, it works well.
We are running a trial with regeneron using afrezza.
What do you think is going on in the sanofi board room regarding their diabetes unit?
|
|
|
|
Post by mbseeking on Nov 2, 2015 9:58:10 GMT -5
I read somewhere that sanofi has a huge plate of new products to introduce.. much more than they have historically. A tall order even for a large pharma like SNY. It could explain their lack of attention to Afrezza so far.
Now if their whole diabetes unit is hurting , the chips are down, if their leader takes defence rather than offence I'm thinking he may focus on the things that they produce themselves.
Could be 1. They announce 11 / 6 they are not pursuing 2. MNKD confirms at conference call 11/9. 3. Later in Nov MNKD (BoD) will decide how to proceed.
This might explain the TASE listing, especially if it goes get an extra $100M of cash by listing there (if new stock is issued to be be bought up by TASE index funds e.g. TASE75 etc) . This would give MNKD a cushion whilst it settles on a new sales / marketing strategy in 2016.
Of course , I'm merely speculating.
|
|
|
|
Post by peppy on Nov 2, 2015 10:06:31 GMT -5
Thanks, I want a discussion.
could be Afrezza goes on as planned, studies done, Europe applied for, insurance coverage improved, more advertising.
could be mannkind will announce an additional technosphere alliance.
The TASE listing was that an additional capital raise for Mannkind?
|
|
